Mobilizing the older patient with myeloma.

[1]  B. Barlogie,et al.  Collection of Peripheral Blood Stem Cells in 668 Patients with Multiple Myeloma Treated on Total Therapy II (UARK 98-026). , 2004 .

[2]  B. Barlogie,et al.  Hematopoietic Progenitor Cell (HPC) Mobilization after Initial Therapy of Multiple Myeloma Including Velcade: Ability to Collect HPC as a Function of Velcade Dosing. , 2004 .

[3]  A. Bhandoola,et al.  Circulating hematopoietic progenitors with T lineage potential , 2004, Nature Immunology.

[4]  F. Chiafari,et al.  The lower limit of residual white blood cell counting: how low is low? , 2004, Transfusion.

[5]  N. Kröger,et al.  Kinetics of G–CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte‐stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study , 2004, Transfusion.

[6]  J. Abkowitz,et al.  Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. , 2003, Blood.

[7]  D. Follmann,et al.  G‐CSF‐induced spleen size changes in peripheral blood progenitor cell donors , 2003, Transfusion.

[8]  F. Petersen,et al.  An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors , 2003, Transfusion.

[9]  S. Leitman,et al.  Analysis of PBPC cell yields during large‐volume leukapheresis of subjects with a poor mobilization response to filgrastim , 2003, Transfusion.

[10]  B. Barlogie,et al.  Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen , 2003, British journal of haematology.

[11]  O. Rick,et al.  Leukapheresis after high‐dose chemotherapy and autologous peripheral blood progenitor cell transplantation: a novel approach to harvest a second autograft , 2003, Transfusion.

[12]  A. Balber,et al.  231ABC-Transporter mediated efflux of aldehyde dehydrogenase reaction product: Implications for enumeration and isolation of functional blood progenitor cells , 2003 .

[13]  I. Petit,et al.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. , 2002, Experimental hematology.

[14]  S. Heimfeld,et al.  Enumeration of HPC in mobilized peripheral blood with the Sysmex SE9500 predicts final CD34+ cell yield in the apheresis collection , 2000, Bone Marrow Transplantation.

[15]  S. Soong,et al.  Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Richardson,et al.  Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  A. Grañena,et al.  Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. , 1999, Blood.

[18]  O. Colvin,et al.  Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Robert J. Moore,et al.  Osteoclast-Mediated Bone Resorption Is Stimulated During Short-Term Administration of Granulocyte Colony-Stimulating Factor But Is Not Responsible for Hematopoietic Progenitor Cell Mobilization , 1998 .

[20]  H. Nakauchi.  Hematopoietic stem cells: Are they CD34-positive or CD34-negative? , 1998, Nature Medicine.

[21]  B. Meisenberg,et al.  A combination of low‐dose cyclophosphamide and colony‐stimulating factors is more cost‐effective than granulocyte‐colony‐stimulating factors alone in mobilizing peripheral blood stem and progenitor cells , 1998, Transfusion.

[22]  J. Kearney,et al.  AC133, a novel marker for human hematopoietic stem and progenitor cells. , 1997, Blood.

[23]  G. Pihan,et al.  Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  A. Ho,et al.  Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both. , 1996, Experimental hematology.

[25]  R. Geha,et al.  Large‐volume leukapheresis in pediatric patients: processing more blood diminishes the apparent magnitude of intra‐apheresis recruitment , 1996, Transfusion.

[26]  R. Möhle,et al.  Estimation of the Progenitor Cell Yield in a Leukapheresis Product by Previous Measurement of CD34+ Cells in the Peripheral Blood , 1996, Vox sanguinis.

[27]  R. Champlin,et al.  Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures , 1996, Transfusion.

[28]  D. Stroncek,et al.  Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.

[29]  S. Bentley,et al.  North American Multicenter Study on flow cytometric enumeration of CD34+ hematopoietic stem cells. , 1996, Journal of hematotherapy.

[30]  H. Goldschmidt,et al.  Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. , 1996, Bone marrow transplantation.

[31]  D. Huhn,et al.  Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Lacor,et al.  The absolute number of circulating CD34+ cells predicts the number of hematopoietic stem cells that can be collected by apheresis. , 1996, Bone marrow transplantation.

[33]  R. Storb,et al.  Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. , 1996, Bone marrow transplantation.

[34]  M. Offidani,et al.  Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. , 1995, Bone marrow transplantation.

[35]  J. Armitage,et al.  Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies. , 1995, Experimental hematology.

[36]  C. Richard,et al.  Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse. , 1995, Bone marrow transplantation.

[37]  A. Prentice,et al.  Osteoporosis in severe congenital neutropenia treated with granulocyte colony‐stimulating factor , 1995, British journal of haematology.

[38]  B. Barlogie,et al.  Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.

[39]  M. Goormastic,et al.  Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. , 1994, Bone marrow transplantation.

[40]  C. Richard,et al.  Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies. , 1993, Bone marrow transplantation.

[41]  C. Hillyer,et al.  CD34+ progenitors and colony‐forming units‐granulocyte macrophage are recruited during large‐volume leukapheresis and concentrated by counterflow centrifugal elutriation , 1993, Transfusion.

[42]  S. Kondo,et al.  Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. , 1993, The Journal of clinical investigation.

[43]  G. Rosner,et al.  Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. , 1993, Blood.

[44]  George Morstyn,et al.  Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor , 1989 .

[45]  E. Kedar,et al.  The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z). , 1989, Bone marrow transplantation.

[46]  J. Cebon,et al.  Pharmacology of the colony-stimulating factors. , 1989, Trends in pharmacological sciences.

[47]  J. Villeval,et al.  Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapy. , 1988, Behring Institute Mitteilungen.

[48]  I. Bruns,et al.  Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma , 2005, Bone Marrow Transplantation.

[49]  D. Link,et al.  Stem cell mobilization. , 2003, Hematology. American Society of Hematology. Education Program.

[50]  T. Papayannopoulou,et al.  Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. , 2000, Seminars in hematology.

[51]  D. Linch,et al.  Remobilization of poor stem cell mobilizers is clinically worthwhile. , 1999 .

[52]  J. Winter,et al.  Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.